Cytokinetics scores late-stage win in non-obstructive HCM as BMS plans Camzyos restart

Cytokinetics’ Phase III success with Myqorzo marks the first late-stage win for a therapeutic in non-obstructive hypertrophic cardiomyopathy, an indication that has historically proved difficult for drug developers. The data also sharpen the competitive picture with BMS, which said last week it plans to restart development of Camzyos in the indication after a Phase III miss last year. 

Shares of Cytokinetics Inc. (NASDAQ:CYTK) rose 17% Monday, lifting its market cap to over $9.5 billion, after announcing that Myqorzo aficamten met both primary endpoints in the Phase III ACACIA-HCM study to treat non-obstructive hypertrophic cardiomyopathy (HCM)...